2585-24-2

Usage

Uses

Used in Chemical Synthesis:
4-Nitro-N-propylbenzamide is used as an intermediate in the synthesis of 4-amino-N-substituted amines. This application is particularly relevant in the pharmaceutical and chemical industries, where these amines can be further utilized to create a wide range of products, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-Nitro-N-propylbenzamide is used as a key intermediate for the synthesis of various drug candidates. Its unique structure allows for the development of novel compounds with potential therapeutic applications, such as antibiotics, anti-inflammatory agents, and other therapeutic molecules.
Used in Catalyst Development:
4-Nitro-N-propylbenzamide may also find use in the development of catalysts for various chemical reactions. Its nitro group and propyl chain can be exploited to design catalysts with specific selectivity and activity, which can be applied in the production of fine chemicals and pharmaceuticals.
Used in Research and Development:
As a benzamide derivative, 4-Nitro-N-propylbenzamide can be employed in research and development efforts to explore its potential as a building block for new molecules with unique properties. This can lead to the discovery of new compounds with applications in various industries, such as materials science, electronics, and biotechnology.

InChI:InChI=1/C10H12N2O3/c1-2-7-11-10(13)8-3-5-9(6-4-8)12(14)15/h3-6H,2,7H2,1H3,(H,11,13)

Upstream product

• 107-10-8 propylamine 
• 122-04-3 4-nitro-benzoyl chloride 
• 555-16-8 4-nitrobenzaldehdye 
• 13277-61-7 p-Nitrobenzoyl bromide 
• 24433-80-5 Methyl-N-(propyl)-propanimidat 

Downstream Products

• 38681-78-6 N-n-propyl 4-aminobenzamide 
• 62869-74-3 [(4-nitrophenyl)methyl](propyl)amine 
• 1009886-19-4 4-(4-oxoquinazolin-3(4H)-yl)-N-propylbenzamide 

Relevant academic research and scientific papers

Spectroscopic behavior of acid-base indicators after immobilization on glass supports

This paper describes an extensive spectrophotometric study on several acid-base indicators immobilized, by means of a silylation process, on quartz powder and on controlled pore glass. The spectrophotometric properties of the immobilized indicators are at

Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations

We report here an extensive structure-activity relationship study of balsalazide, which was previously identified in a high-throughput screening as an inhibitor of Sirt5. To get a closer understanding why this compound is able to inhibit Sirt5, we initially performed docking experiments comparing the binding mode of a succinylated peptide as the natural substrate and balsalazide with Sirt5 in the presence of NAD+. Based on the evidence gathered here, we designed and synthesized 13 analogues of balsalazide, in which single functional groups were either deleted or slightly altered to investigate which of them are mandatory for high inhibitory activity. Our study confirms that balsalazide with all its given functional groups is an inhibitor of Sirt5 in the low micromolar concentration range and structural modifications presented in this study did not increase potency. While changes on the N-aroyl-β-alanine side chain eliminated potency, the introduction of a truncated salicylic acid part minimally altered potency. Calculations of the associated reaction paths showed that the inhibition potency is very likely dominated by the stability of the inhibitor-enzyme complex and not the type of inhibition (covalent vs. non-covalent). Further in-vitro characterization in a trypsin coupled assay determined that the tested inhibitors showed no competition towards NAD+ or the synthetic substrate analogue ZKsA. In addition, investigations for subtype selectivity revealed that balsalazide is a subtype-selective Sirt5 inhibitor, and our initial SAR and docking studies pave the way for further optimization.

Dual targeting of PTP1B and glucosidases with new bifunctional iminosugar inhibitors to address type 2 diabetes

The diffusion of type 2 diabetes (T2D) throughout the world represents one of the most important health problems of this century. Patients suffering from this disease can currently be treated with numerous oral anti-hyperglycaemic drugs, but none is capab

Convenient metal-free direct oxidative amidation of aldehyde using dibromoisocyanuric acid under mild conditions

A facile method for the direct synthesis of amides from aldehydes is described. Amide bonds were synthesized by an oxidative amidation in the presence of dibromoisocyanuric acid (DBI). Treatment of aromatic and aliphatic aldehydes with dibromoisocyanuric acid generated acyl bromide intermediates, which were employed to react with a variety of secondary and primary amines to give amides. Through this reaction method, various amides were synthesized directly from aldehydes under mild conditions in high yields and short times. This facile and efficient procedure provides potential strategy for the direct synthesis of amides from aldehydes.

Catalyst-free amidation of aldehyde with amine under mild conditions

A highly efficient, catalyst-free and one-pot procedure for the direct synthesis of amides from aldehydes and amines under mild conditions has been developed. Both aliphatic and aromatic aldehydes with primary or secondary amines are successfully converted to the corresponding amides, and it is observed that reactions can proceed in either aqueous or organic media.

A mild and clean method for oxidative formation of amides from aldehydes and amines

A metal-free direct oxidative formation of amides from aldehydes and amines using a hypervalent iodine(III) reagent or an ion-supported hypervalent iodine(III) reagent as a recyclable oxidant under mild conditions is reported. Georg Thieme Verlag Stuttgart.

Thermosensitive recording material and novel color developer compounds

Disclosed is a thermosensitive recording material comprising a sheet-shaped support and a thermosensitive recording layer which is formed on at least one surface of the support and comprises a colorless or light-colored dye precursor and a color developer capable of reacting with the dye precursor and inducing color formation therein upon application of heat thereto, the color developer comprising a compound represented by the following formula (I) or analog thereof:: The thermosensitive recording material has high sensitivity and can prevent white background portions from coloring and recorded images from decolorizing in an environmental resistance test.

Benzamide therapeutics for the treatment of inflammatory bowel disease

Benzamides are disclosed to be useful for treating and preventing inflammatory bowel disease.

Aminobenzamide compounds for the treatment of neurodegenerative disorders

A group of benzamide compounds are disclosed which are useful for treating neurodegenerative disorders. Methods for making these compounds are provided. These materials are formed into pharmaceutical compositions for oral or intravenous administration to patients suffering from conditions such as Parkinson's disease which can exhibit themselves as progressive loss of central nervous system function. The compounds can arrest or slow the progressive loss of function.

Anticonvulsant activity of some 4-aminobenzamides

A series of 4-aminobenzamides of some simple primary and secondary amines were prepared and evaluated for anticonvulsant effects. The compounds were tested in mice against seizures induced by electroshock and pentylenetetrazole (metrazole) and in the rotorod assay for neurologic deficit. For those N-alkyl amides tested, 4-amino-N-amylbenzamide was the most potent against maximal electroshock seizures (MES): ED50=42.98 mg/kg; however, the N-cyclohexylbenzamide showed the greatest protective index (PI=TD50/ED50), 2.8. The introduction of a second aromatic ring produced more potent compounds, with d,l-4-amino-N-(α-methylbenzyl)-benzamide showing the highest level of activity. This compound has an anti-MES ED50 of 18.02 mg/kg in mice when administered intraperitoneally (ip) and a TD50 of 170.78 mg/kg (PI=9.5) in the same species. These data compare quite favorably with those for phenobarbital and phenytoin in the same assays.